Pasithea Therapeutics is a biotechnology company focused on the research and discovery of treatments for psychiatric and neurological disorders. Co.'s secondary operations focus on establishing anti-depression clinics across the U.K. and providing business support services to similar entities in the U.S., using trained pharmacists to administer intravenous infusions of ketamine. The KTTA stock yearly return is shown above.
The yearly return on the KTTA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KTTA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|